T1	Participants 194 348	out-patients suffering from moderate to severe depression were treated with the objective of assessing the new drug's therapeutically effective dose range
T2	Participants 392 509	fourteen patients were assigned to receive diclofensine and thirteen to receive maprotiline in a double-blind design.
T3	Participants 1208 1283	patients in whom a psycho-energizing and mood alleviating effect is desired
